Basilea Pharmaceutica AG
Basilea Pharmaceutica AG (BPMUF) Financial Performance & Income Statement Overview
Analyze Basilea Pharmaceutica AG (BPMUF) financial statements (income, balance sheet, and cash flow) across both yearly and quarterly periods.
Basilea Pharmaceutica AG (BPMUF) Income Statement & Financial Overview
View the income breakdown for Basilea Pharmaceutica AG BPMUF across both annual and quarterly reports.
| Metric | Q4 2024 | Q2 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|
| Revenue | $132.25M | $76.29M | $72.73M | $36.36M |
| Cost of Revenue | $64.11M | $18.12M | $16.80M | $36.59M |
| Gross Profit | $68.14M | $58.17M | $55.93M | -$227000.00 |
| Gross Profit Ratio | $0.52 | $0.76 | $0.77 | -$0.006 |
| R&D Expenses | $43.55M | $33.60M | $56.38M | $28.19M |
| SG&A Expenses | $15.96M | $15.32M | $17.24M | $7.96M |
| Operating Expenses | $16.22M | $15.32M | $73.62M | $8.37M |
| Total Costs & Expenses | $80.33M | $67.04M | $90.42M | $44.97M |
| Interest Income | $0.00 | $0.00 | $1.20M | $2.10M |
| Interest Expense | $0.00 | $0.00 | $9.76M | $0.00 |
| Depreciation & Amortization | $793500.00 | $638500.00 | $1.72M | $312000.00 |
| EBITDA | $52.98M | $10.15M | -$7.88M | -$7.88M |
| EBITDA Ratio | $0.40 | $0.13 | -$0.22 | -$0.22 |
| Operating Income | $51.92M | $9.26M | -$17.69M | -$8.19M |
| Operating Income Ratio | $0.39 | $0.12 | -$0.24 | -$0.23 |
| Other Income/Expenses (Net) | $1.01M | -$1.93M | $6.99M | -$2.52M |
| Income Before Tax | $52.94M | $7.33M | -$21.41M | -$10.70M |
| Income Before Tax Ratio | $0.40 | $0.10 | -$0.29 | -$0.29 |
| Income Tax Expense | -$3.92M | -$13.41M | -$17000.00 | $8500.00 |
| Net Income | $56.86M | $20.74M | -$21.39M | -$10.69M |
| Net Income Ratio | $0.43 | $0.27 | -$0.29 | -$0.29 |
| EPS | $4.20 | $1.72 | -$1.78 | -$0.95 |
| Diluted EPS | $4.09 | $1.50 | -$1.78 | -$0.89 |
| Weighted Avg Shares Outstanding | $13.52M | $12.09M | $12.002M | $11.23M |
| Weighted Avg Shares Outstanding (Diluted) | $13.89M | $13.82M | $12.002M | $12.005M |
Over the last four quarters, Basilea Pharmaceutica AG achieved steady financial progress, growing revenue from $36.36M in Q3 2023 to $132.25M in Q4 2024. Gross profit stayed firm with margins at 52% in Q4 2024 versus -1% in Q3 2023. Operating income totaled $51.92M in Q4 2024, maintaining a 39% margin over recent quarters. Despite shifts in R&D and SG&A costs, EBITDA stayed strong at $52.98M. Net income rose to $56.86M, with EPS at $4.20. Disciplined expense strategies and efficient operations ensured sustained profitability and long-term financial stability.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan